Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Schering-Plough Corporation
Current Parent Company: Merck
Parent at the Time of the Penalty Announcement:  subscribe to see this data field
Recap of Ownership Changes:  subscribe to see this data field
Penalty: $435,000,000
Year: 2006
Date: August 29, 2006
Offense Group: healthcare-related offenses
Primary Offense: off-label or unapproved promotion of medical products
Secondary Offense: fraud
Mega-Scandal: Improper Drug Marketing
Violation Description: Schering-Plough agreed to pay $435 million to resolve criminal charges and civil liabilities in connection with illegal sales and marketing programs for its drugs Temodar (used in the treatment of brain tumors and metastases) and Intron A (used in treatment of superficial bladder cancer and hepatitis C). The resolution also pertained to Medicaid fraud involving Schering's drugs Claritin RediTabs, a non-sedating antihistamine, and K-Dur, used in treating stomach conditions.
Level of Government: federal
Action Type: agency action
Agency: U.S. Attorney-District of Massachusetts
Civil or Criminal Case: civil and criminal
HQ Country of Current Parent: USA
HQ State of Current Parent: New Jersey
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.